Intercytex

Intercytex (ICX) is a UK-based healthcare company using proprietary cell therapy technology to develop innovative products to restore and regenerate skin and hair.

Intercytex was formed in 1999 by Paul Kemp (BSc, PhD), who had previously developed Apligraf, the first cell-based product approved by the US Food and Drug Administration. He is currently the Chief Scientific Officer.

ICX's flagship Hair Multiplication technology is ICX-TRC, though they have other unrelated targets using similar techniques:

ICX-PRO - Venous leg ulcers, Diabetic foot ulcers
ICX-RHY - Facial Rejuvination
ICX-SKN - Grafts

All Intercytex products are derived from unmodified human cells.

Business offices are in Cambridge, manufacturing is carried out in Manchester.

1 Venture Captial Funding
2 Timeline
3 News
- 3.1 Financial News
4 See Also
5 References

[edit] Venture Captial Funding

A partial list of entities that helped supply the original £27m of venture capital:

Johnson & Johnson
Alan Goodman's Avlar BioVentures in Cambridge
Sir Chris Evans' Merlin BioSciences
3i
Scottish Equity
Unnamed Far East entities

[edit] Timeline

May 2007 - BioLife Solutions Inc., a leading developer and marketer of proprietary hypothermic storage and cryopreservation media products for cells and tissues, today announced a supply and licensing agreement with Intercytex Group plc. ^[1]